A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Soo LimSeung Hwan LeeKyung-Wan MinChang Beom LeeSang Yong KimHye Jin YooNan Hee KimJae Hyeon KimSeungjoon OhJong Chul WonHyuk-Sang KwonMi Kyung KimJung Hwan ParkIn-Kyung JeongSungrae KimPublished in: Diabetes, obesity & metabolism (2024)
Adjunctive pioglitazone treatment in T2DM inadequately controlled with metformin and dapagliflozin demonstrates considerable glycaemic improvement, metabolic benefits, and a low risk of hypoglycaemia. These advantages must be weighed against the potential for weight gain and increased waist circumference.
Keyphrases
- double blind
- placebo controlled
- body mass index
- weight gain
- clinical trial
- type diabetes
- phase iii
- birth weight
- phase ii
- study protocol
- phase ii study
- physical activity
- body weight
- weight loss
- open label
- stem cells
- squamous cell carcinoma
- randomized controlled trial
- adipose tissue
- climate change
- cell therapy
- metabolic syndrome
- locally advanced